Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives $22.57 Average Target Price from Brokerages

Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) have received an average recommendation of “Moderate Buy” from the seven research firms that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $22.57.

Several equities research analysts have weighed in on the company. JPMorgan Chase & Co. upped their target price on Neumora Therapeutics from $20.00 to $22.00 and gave the stock an “overweight” rating in a research note on Monday, March 18th. William Blair restated an “outperform” rating on shares of Neumora Therapeutics in a research note on Friday, April 12th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $31.00 target price on shares of Neumora Therapeutics in a research note on Thursday, March 28th.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of NMRA. FMR LLC bought a new position in Neumora Therapeutics during the 3rd quarter worth $79,360,000. Johnson & Johnson bought a new position in shares of Neumora Therapeutics in the 3rd quarter worth about $12,870,000. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST bought a new position in shares of Neumora Therapeutics in the 3rd quarter worth about $46,692,000. Citigroup Inc. bought a new position in shares of Neumora Therapeutics in the 3rd quarter worth about $203,000. Finally, Avidity Partners Management LP bought a new position in shares of Neumora Therapeutics in the 3rd quarter worth about $25,398,000. 47.65% of the stock is currently owned by institutional investors.

Neumora Therapeutics Price Performance

Shares of NASDAQ:NMRA opened at $9.46 on Friday. The business’s 50 day simple moving average is $14.44 and its 200 day simple moving average is $14.11. Neumora Therapeutics has a 1 year low of $8.82 and a 1 year high of $21.00.

Neumora Therapeutics (NASDAQ:NMRA) last released its earnings results on Thursday, March 7th. The company reported ($0.71) earnings per share for the quarter, topping the consensus estimate of ($0.76) by $0.05. On average, equities analysts predict that Neumora Therapeutics will post -1.48 EPS for the current year.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.